GlaxoSmithKline and Alector have announced a global partnership to develop and commercialize two monoclonal antibodies: AL001 and AL101. The mAbs are designed to elevate progranulin (PGRN) – a key regulator of immune activity in the brain that has genetic links to multiple neurodegenerative disorders (1). PGRN is considered one of the most attractive targets for new immuno-neurology treatments.
Enrolment is currently underway for a phase III trial of AL001 in people at risk of frontotemporal dementia due to a PGRN gene mutation. AL001 is also being studied in trials of patients with symptomatic frontotemporal dementia with a mutation in the C9orf72 gene, as well as in patients with amyotrophic lateral sclerosis. Meanwhile, AL101 is being investigated to treat patients with more prevalent neurodegenerative diseases, including Parkinson’s and Alzheimer’s.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
References
- GlaxoSmithKline, “GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases” (2021). Available at: https://bit.ly/3qORbeo
